Skip to main content
Journal cover image

Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training.

Publication ,  Journal Article
Jones, WS; Duscha, BD; Robbins, JL; Duggan, NN; Regensteiner, JG; Kraus, WE; Hiatt, WR; Dokun, AO; Annex, BH
Published in: Vasc Med
April 2012

The aims of this study were twofold: (1) to identify whether peripheral artery disease (PAD) patients had increased muscle concentration of angiogenic VEGF-A, anti-angiogenic VEGF₁₆₅b or VEGF receptor 1 (VEGF-R1) when compared with control subjects, and (2) to evaluate whether exercise training in PAD patients was associated with changes in muscle concentration of VEGF-A, VEGF₁₆₅b or VEGF-R1. At baseline, 22 PAD and 30 control subjects underwent gastrocnemius muscle biopsy. Twelve PAD patients were treated with supervised exercise training (SET) and underwent muscle biopsy after 3 weeks and 12 weeks of training and had sufficient tissue to measure VEGF-A, VEGF₁₆₅b and VEGF-R1 concentrations in skeletal muscle lysates by ELISA. Muscle concentrations of VEGF-A and VEGF₁₆₅b were similar in PAD patients versus controls at baseline. At both time points after the start of SET, VEGF-A levels decreased and there was a trend towards increased VEGF₁₆₅b concentrations. At baseline, VEGF-R1 concentrations were lower in PAD patients when compared with controls but did not change after SET. Skeletal muscle concentrations of VEGF-A are not different in PAD patients when compared with controls at baseline. SET is associated with a significant reduction in VEGF-A levels and a trend towards increased VEGF₁₆₅b levels. These somewhat unexpected findings suggest that further investigation into the mechanism of vascular responses to exercise training in PAD patients is warranted.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Vasc Med

DOI

EISSN

1477-0377

Publication Date

April 2012

Volume

17

Issue

2

Start / End Page

94 / 100

Location

England

Related Subject Headings

  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Time Factors
  • Recovery of Function
  • Peripheral Arterial Disease
  • North Carolina
  • Neovascularization, Physiologic
  • Muscle, Skeletal
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jones, W. S., Duscha, B. D., Robbins, J. L., Duggan, N. N., Regensteiner, J. G., Kraus, W. E., … Annex, B. H. (2012). Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training. Vasc Med, 17(2), 94–100. https://doi.org/10.1177/1358863X11436334
Jones, W Schuyler, Brian D. Duscha, Jennifer L. Robbins, Natasha N. Duggan, Judith G. Regensteiner, William E. Kraus, William R. Hiatt, Ayotunde O. Dokun, and Brian H. Annex. “Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training.Vasc Med 17, no. 2 (April 2012): 94–100. https://doi.org/10.1177/1358863X11436334.
Jones, W. Schuyler, et al. “Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training.Vasc Med, vol. 17, no. 2, Apr. 2012, pp. 94–100. Pubmed, doi:10.1177/1358863X11436334.
Jones WS, Duscha BD, Robbins JL, Duggan NN, Regensteiner JG, Kraus WE, Hiatt WR, Dokun AO, Annex BH. Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training. Vasc Med. 2012 Apr;17(2):94–100.
Journal cover image

Published In

Vasc Med

DOI

EISSN

1477-0377

Publication Date

April 2012

Volume

17

Issue

2

Start / End Page

94 / 100

Location

England

Related Subject Headings

  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor A
  • Treatment Outcome
  • Time Factors
  • Recovery of Function
  • Peripheral Arterial Disease
  • North Carolina
  • Neovascularization, Physiologic
  • Muscle, Skeletal
  • Middle Aged